Over the last few years, as Big Pharma has reorganized, outsourcing has become a bigger and bigger part of the biopharma world. The CRO business is undergoing a big shakeout as major players emerge to compete for global contracts. Manufacturing outsourcing is reshaping the industry around the world. And every facet of drug development has been undergoing deep changes, as large numbers of developers--from the virtual biotech to the vast pharma company--rethink the way they do business and find ways to become more efficient.
That, in a nutshell, is what's behind our decision to launch FierceCRO. Every week we'll be giving you a close look at all the news and analysis in the field. Forging ties with outsourcing partners is one of the most challenging aspects of biopharma today. We'll give readers the lowdown on the good, the bad and the plain ugly as you find your own way through a complex and challenging industry.
In the days leading up to today's launch, we quickly gathered more than 5,000 subscribers to FierceCRO, making this our most successful launch ever at FierceMarkets. That kind of interest underscores just how avid readers are about outsourcing news. We won't let you down. - John Carroll (email | twitter)